Introduction The aim of this international collaborative effort was to report 36-month longitudinal changes using the 6MWT in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53. Materials and methods Of the 92 patients included in the study, 24 had deletions amenable to skip exon 44, 27 exon 45, 18 exon 51, and 28 exon 53. Five patients with a single deletion of exon 52 were counted in both subgroups skipping exon 51 and 53. Results The difference between subgroups amenable to skip different exons was not significant at 12 months but became significant at both 24 (p0.05) and 36 months (p0.01). Discussion Mutations amenable to skip exon 53 had lower baseline values and more negative changes than...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
peer reviewedINTRODUCTION: The aim of this study was to report 36-month longitudinal changes using t...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Introduction: The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne M...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
peer reviewedINTRODUCTION: The aim of this study was to report 36-month longitudinal changes using t...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Introduction: The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne M...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...